In the sensitivity analyses, the primary outcome analysis was repeated for the PP sample, defined as participants who followed the study protocol with full adherence, attending all study visits with no substantial interruptions in treatment as monitored from the drug dose diary
Polycystic Ovary Syndrome (PCOS) Semaglutide is being explored as a potential treatment for Polycystic Ovary Syndrome (PCOS), a condition frequently associated with insulin resistance and obesity
We understand that achieving your desired goals often involves more than just one approach
If you notice anything out of the ordinary or are experiencing symptoms such as severe abdominal or pelvic pain, heavy bleeding, or lightheadedness, contact your doctor or OBGYN immediately
Researchers observed that weight loss with semaglutide ranged from 9.6 to 17.1% in participants without gastrointestinal AEs and from 11.4 to 17.7% in those with gastrointestinal AEs, suggesting gastrointestinal AEs appeared to contribute little to the weight-loss benefit of semaglutide, which were consistent with previous studies that the weight-loss effects of semaglutide in patients with obesity and/or T2DM indicated little contribution of gastrointestinal AEs ( Clinical prioritization of the disproportionality signals In this study, we innovatively used a rating scale to further analyze the disproportionality signals in order to prioritize safety signals and avoid unnecessary warnings